可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and matural history of atrial fibrillation: clinical implications [J]. J Am Coll Cardiol, 2001, 37(2):371-378.
[2] Aviles RJ, Martin DO, AppersonHansen C ,et al. Inflammation as a risk factor for atrial fibrillation [J]. Circulation, 2003, 108(24):3006-3010.
[3] Chung MK, Martin DO, Sprecher D, et al. Creactive protein elevation in patients with atrial arrgythmias: Inflammatory mechanisms and persistence of atrial fibrillation[J]. Circulation, 2001, 104(24):2886-2891.
[4] Sata N, Hamada N, Horinouchi T, et al. Creactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation?[J]. Jpn Heart J, 2004, 45(3):441-445.
[5] Watanabe T, Takeishi Y, Hirono O, et al. Creactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation [J]. Heart Vessels, 2005, 20(2):45-49.
[6] 贾新未,王晓娜,史红云,等.血浆肾素-血管紧张素-醛固酮水平对心房颤动转复的影响[J]. 心脏杂志, 2006, 18(5):547-549.
[7] Healey JS, Morillo CA, Connolly SJ, et al. Role of the reninangiotensin aldosterone system in atrial fibrillation and cardiac remodeling[J]. Curr Opin Cardiol, 2005, 20(1):31-37.